Boston, MA -- (SBWIRE) -- 08/02/2013 -- Chembio Diagnostics, Inc. (Chembio) together with its wholly owned subsidiary Chembio Diagnostic Systems, Inc., undertakes the development, manufacturing and marketing of point-of-care diagnostic (POCs) tests that detect infectious diseases. The major commercially available products of the company include four rapid tests for the detection of HIV antibodies, two rapid tests for the detection of syphilis and a rapid test for the detection of canine leishmaniasis. Its new product pipeline is based on Dual Path Platform (DPP) technology.